![](/images/graphics-bg.png)
A Multicenter, Randomized, Parallel-Group Trial Assessing Compliance, Tolerability, Safety, and Efficacy to Treatment with Grass Allergy Tablets in 261 Patients with Grass Pollen Rhinoconjunctivitis
Joint Authors
Pecora, Silvia
Alesina, Roberta
Milani, Massimo
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-11-09
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Background.
Allergen-specific sublingual immunotherapy (SLIT) is considered a causal treatment of respiratory allergies.
Compliance to the SLIT is an important aspect for a positive clinical outcome.
Study Aim.
To evaluate if compliance with grass Allergy Immunotherapy Tablet (AIT) can be increased by providing an electronic compliance device (CED) (Memozax; a tablet-container with a programmable daily acoustic alarm).
Patients and Methods.
261 patients with grass allergy were enrolled and randomized (1 : 1) to 1-year treatment with AIT (Grazax) using a CED (group A; n=122) or without (Group B, n=139).
Compliance was measured through tablet count at each visit.
Results.
The 12-month compliance, mean (SD), in group A was 83% (21) and 83% (24) in group B.
A total of 81% of patients reported a significant clinical improvement of symptoms after treatment in comparison with the previous year.
No severe adverse reactions were observed in the study.
Conclusion.
Compliance to the treatment with AIT administered for 12 consecutive months is in general good.
The use of CED is not associated with a greater compliance.
AIT treatment was associated with a significant clinical improvement in >80% of patients with a good tolerability and safety profile.
American Psychological Association (APA)
Alesina, Roberta& Milani, Massimo& Pecora, Silvia. 2011. A Multicenter, Randomized, Parallel-Group Trial Assessing Compliance, Tolerability, Safety, and Efficacy to Treatment with Grass Allergy Tablets in 261 Patients with Grass Pollen Rhinoconjunctivitis. Journal of Allergy،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-489395
Modern Language Association (MLA)
Alesina, Roberta…[et al.]. A Multicenter, Randomized, Parallel-Group Trial Assessing Compliance, Tolerability, Safety, and Efficacy to Treatment with Grass Allergy Tablets in 261 Patients with Grass Pollen Rhinoconjunctivitis. Journal of Allergy No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-489395
American Medical Association (AMA)
Alesina, Roberta& Milani, Massimo& Pecora, Silvia. A Multicenter, Randomized, Parallel-Group Trial Assessing Compliance, Tolerability, Safety, and Efficacy to Treatment with Grass Allergy Tablets in 261 Patients with Grass Pollen Rhinoconjunctivitis. Journal of Allergy. 2011. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-489395
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-489395